Long-acting stimulants: development and dosing. - Wikidata - wikimedia - TriplyDB

Long-acting stimulants: development and dosing.

Long-acting stimulants: development and dosing.

http://www.wikidata.org/entity/Q42761512

about

Lisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of Efficacy

P2860

Q26750486-19E23F98-B72F-4367-8B58-70AD870C639C

P2860

Long-acting stimulants: development and dosing.

http://www.wikidata.org/entity/Q42761512

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Long-acting stimulants: development and dosing.

@en

Long-acting stimulants: development and dosing.

@nl

type

label

Long-acting stimulants: development and dosing.

@en

Long-acting stimulants: development and dosing.

@nl

prefLabel

Long-acting stimulants: development and dosing.

@en

Long-acting stimulants: development and dosing.

@nl

P1433

Q42761512-1DAB7FF4-83D6-446D-A3F1-E2A71B9D2FE8

P1476

Q42761512-87C9D123-8088-4732-AA6C-EFAB17C62379

P2093

Q42761512-1F4EF4F1-9672-4E3A-80BD-A227EE915615

P2860

Q42761512-513225AB-9F1E-4107-AD1F-84CDB4EE5EBC

Q42761512-5E5232A7-1588-44B4-833C-71615C3D7BA7

Q42761512-71B98228-DF46-4539-AC3B-B4C45DB47169

Q42761512-8214A15D-8947-4F32-86CA-FA4F40C45AAE

Q42761512-82A77974-AC81-49CC-AE6F-3B99AACEBF20

Q42761512-A7375AC0-4F1C-4889-95F2-56E6330F9656

Q42761512-B9490582-F0C7-4EB6-A290-1E9B677C3B3D

Q42761512-CEA28E4E-701A-40C7-9410-1AE7963FB090

Q42761512-F6FFCD23-8187-495F-8A16-F3D1FAB18147

P304

Q42761512-D43D1164-6531-474A-B513-1D5C1423AC98

P31

Q42761512-D17517C2-274B-4D10-BA33-5D2085E12D27

P433

Q42761512-9FA3C495-1296-4116-92E9-C721C454D312

P478

Q42761512-6F8EF827-1C42-4D62-B759-E06A82D75E40

P577

Q42761512-56055D62-D3A7-4605-A649-8284A9707019

P698

Q42761512-21214B1E-AED8-4465-8BF2-E555F15BEB78

P932

Q42761512-A67584F9-3A9A-44A2-A69C-3D4FCAA82930

P1433

The Canadian child and adolescent psychiatry review = La revue canadienne de psychiatrie de l'enfant et de l'adolescent

P1476

Long-acting stimulants: development and dosing

@en

P2093

James M Swanson

http://www.w3.org/2001/XMLSchema#string

P2860

Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies

Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children.

Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings.

Serum and brain concentrations of methylphenidate: implications for use and abuse.

Evaluation of individual subjects in the analog classroom setting: I. Examples of graphical and statistical procedures for within-subject ranking of responses to different delivery patterns of methylphenidate.

ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study.

Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD.

Pharmacokinetics of SLI381 (ADDERALL XR), an extended-release formulation of Adderall.

A pharmacokinetic/pharmacodynamic study comparing a single morning dose of adderall to twice-daily dosing in children with ADHD.

P304

4-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

Supplement 1

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2005-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19030518

http://www.w3.org/2001/XMLSchema#string

P932

2547091

http://www.w3.org/2001/XMLSchema#string